Targets › MRSA
1 program from 1 company in 1 trial: 1 Phase 4; Infectious disease; next expected readout Jan 2029.
Open in Phaseline: the race on MRSA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Todd C. Lee MD MPH FIDSA | Daptomycin for Injection Lipopeptide antibiotic that disrupts bacterial cell membrane; bactericidal against Gram-po | MRSA | Phase 4 | Staphylococcus Aureus Septicemia | Jan 2029 |
Staphylococcus Aureus Septicemia (1)
small molecule (1)
Todd C. Lee MD MPH FIDSA (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.